CLINICAL DILEMMAS IN HEART FAILURE:

Slides:



Advertisements
Similar presentations
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Advertisements

A Comparison of Angiotensin Receptor-Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
CHARM Program: 3 Component trials comparing candesartan with placebo.
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
analysis from the SHIFT study
SOLVD (Studies of Left Ventricular Dysfunction)
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Entresto® (sacubitril & valsartan)
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Change in SBP (mmHg) OmapatrilatEnalapril HCTZ (n = 2476) Change in Systolic BP at Week 24 for Patients Receiving Adjuncts After Week 8 (All Randomized.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Natural History of Heart Failure
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
Eric J Robinson, M.D. Cardiologist April 25, 2015
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
Heart Failure Management
Prior Trials of RAAS Inhibitors
Emerging Concepts in Heart Failure
EMPHASIS-HF Extended Follow-up
A CASE CHALLENGE IN HFrEF:
Biomarkers in Heart Failure
Select Topics in Cardiovascular Medicine
Cost Effectiveness and Optimal Outcomes in HF
Section III: Neurohormonal strategies in heart failure
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
T2DM and CV Outcomes Trials: A Deep Dive!
Treating HFrEF: Challenges Faced
Treatment Options to Consider
Exploring Emerging Treatments for Hyperkalemia
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.
The Importance of Getting the Dose Right in HF
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Case #1 Case #1 (cont) Case #1 (cont)
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Challenging the Myths in Heart Failure With Reduced Ejection Fraction
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
Iron Deficiency in Heart Failure
Section III: Neurohormonal strategies in heart failure
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.
PAH Pathways: What Do the Data Tell Us?”
Uptitration of Medications in HF: Start Low but Aim High and Stay High
In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Top Tips in Evidence-Based Care for HFrEF
Key Data on Improving Outcomes in HF Patients
Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.
What Do the Guidelines Say About The Role of the HF Nurse?
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

CLINICAL DILEMMAS IN HEART FAILURE:

ESC HF Guidelines: Changes From 2012 for Chronic HF Management

Evolution of Neurohormonal Blockers

Neurohormonal Blockade in HF

Impact of Beta-Blockade, ACEi, and ARB Therapy in Chronic HF

MRAs: Mechanism of Action

RALES: Mortality Reduction With Spironolactone

MRAs in Heart Failure

Neurohormonal Activation: Good and Bad

PARADIGM-HF Primary Results: Significant Reduction in Primary Endpoints, CV Death, and All-Cause Mortality

SOLVD: Enalapril vs Placebo in HFrEF

PARADIGM-HF: Robustness of the Results

ACEi - ARNi in Chronic HF: A 25+ Year Story

Terminology Within Heart Failure

PARADIGM-HF: Secondary Outcomes and Patient-Reported Outcomes

PARADIGM-HF: NYHA Functional Class at Baseline

ESC Guidelines for HF: Pharmacological Treatments in Symptomatic (NYHA Class II-IV) HFrEF - Target Dosing

Natriuretic Peptides in HF

Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

PARADIGM-HF: Adverse Events

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.